Thus, our findings confirm the recommendations of the Chinese guidelines for the diagnosis of ALK-positive NSCLC, and the Ventana IHC ALK(D5F3) platform is now employed as a routine diagnostic tool in many hospitals in China. This evidence concerns the gene ALK and non-small cell lung carcinoma.